Why Is CHARLES RIV LABORATO (CRL) Stock Up Today?

CRL stock is up 11.01% at $260.44 as of the latest trade following the company's second-quarter 2026 earnings report. Charles River Laboratories reported non-GAAP earnings per share of $3.02, exceeding estimates by $0.29, and revenue of $1.004 billion, beating expectations by $28.3 million. The company also raised its full-year 2026 guidance for both adjusted earnings and revenue, reflecting stronger-than-expected demand in the biotech sector.

What Happened

Charles River Laboratories filed a Form 8-K on August 5, disclosing preliminary results of operations and financial condition. The report highlighted a significant beat on both earnings and revenue, with non-GAAP EPS at $3.02 and revenue reaching $1.004 billion. The firm raised its 2026 adjusted EPS guidance to a range of $11.15 to $11.45, up from its previous range of $10.80 to $11.30. Additionally, the company increased its full-year revenue guidance to $3.879 billion to $3.920 billion. These updates were cited as the primary catalysts for the stock's sharp rise.

What The Data Shows

The stock opened with a 2.9% gap up at $240.91, following a prior close of $234.12. It reached an intraday high of $268.00 before retreating slightly. Trading volume has reached 0.2 million shares, which is 0.2 times the 3-month average. Despite the stock's recent rally, it remains within its 52-week range of $144.26 to $242.73, suggesting the move is still a sharp rebound rather than a long-term trend. The company's fundamentals remain mixed, with a trailing 12-month net loss and a market cap of $11.1 billion.

What To Watch

The company is expected to provide further details on its strategic direction and biotech demand in the coming quarters. Investors should monitor the next earnings release and any additional guidance updates for clarity on the sustainability of the current momentum.